Explore more about: COVID-19

Mammoth Biosciences has secured an emergency authorization from the FDA for its high-throughput COVID-19 test, which is powered by CRISPR gene-editing enzymes.

NIH RADx Tech Independent Test Assessment Program provides support for FDA authorization of two rapid at-home COVID-19 tests.

The NIH RADx initiative today announced the launch of the When To Test Calculator for Individuals, a companion to the version for organizations introduced last winter. By responding to just a few prompts, the new individual impact calculator indicates whether a person should get a test—now or soon.

NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.

Detect™, Inc., a Connecticut-based health technology company, announced today that the National Institutes of Health (NIH) has selected the Detect™ Covid-19 Test to receive funding from the highly competitive Rapid Acceleration of Diagnostics Initiative (RADxSM).

The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

A new $13.3 million contract from the NIH's Rapid Acceleration of Diagnostics (RADx) initiative will enable the David Geffen School of Medicine at UCLA to expand its capacity to process COVID-19 tests.

In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.

NIH researchers report that the prevalence of COVID-19 in the United States during spring and summer of 2020 far exceeded the known number of cases. For every diagnosed COVID-19 case in this time frame, the researchers estimate that there were 4.8 undiagnosed cases, representing an additional 16.8 million cases by July alone.

This study investigates how the nucleocapsid protein, or N protein, of the SARS-CoV-2 virus packages the viral genome.